Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.

Journal: The Lancet. Oncology
Published Date:

Abstract

BACKGROUND: An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading.

Authors

  • Peter Ström
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Kimmo Kartasalo
    BioMediTech and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
  • Henrik Olsson
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Leslie Solorzano
    Centre for Image Analysis, Uppsala University, Uppsala, 75124, Sweden.
  • Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
  • Daniel M Berney
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • David G Bostwick
    Bostwick Laboratories, Orlando, FL, USA.
  • Andrew J Evans
    Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
  • David J Grignon
    Indiana University, Indianapolis, Indiana.
  • Peter A Humphrey
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
  • Kenneth A Iczkowski
    Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • James G Kench
    Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Central Clinical School, University of Sydney, Sydney, NSW, Australia.
  • Glen Kristiansen
    Institute of Pathology, University Hospital Bonn, Bonn, Germany.
  • Theodorus H van der Kwast
    Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
  • Katia R M Leite
    Department of Urology, Laboratory of Medical Research, University of São Paulo Medical School, São Paulo, Brazil.
  • Jesse K McKenney
    Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Jon Oxley
    Department of Cellular Pathology, Southmead Hospital, Bristol, UK.
  • Chin-Chen Pan
    Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Hemamali Samaratunga
    Aquesta Uropathology and University of Queensland, Brisbane, QLD, Australia.
  • John R Srigley
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Hiroyuki Takahashi
    Department of Pathology, Jikei University School of Medicine, Tokyo, Japan.
  • Toyonori Tsuzuki
    Department of Surgical Pathology, Aichi Medical University Hospital, Aichi 480-1195, Japan. tsuzuki@aichi-med-u.ac.jp.
  • Murali Varma
    Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.
  • Ming Zhou
    Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
  • Johan Lindberg
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Cecilia Lindskog
    Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
  • Pekka Ruusuvuori
    BioMediTech and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
  • Carolina Wählby
    1 Centre for Image Analysis/SciLifeLab, Uppsala University, Uppsala, Sweden.
  • Henrik Grönberg
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology, St Göran Hospital, Stockholm, Sweden.
  • Mattias Rantalainen
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Lars Egevad
    Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Martin Eklund
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: martin.eklund@ki.se.